Daily Bulletin

Men's Weekly

.

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

HONG KONG SAR - Media OutReach - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that Phase III clinical trial of SinoMab's flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.

Business News

The ultimate checklist for launching a digital-first business

If you’re launching a business in 2025, chances are it’s going to be digital-first. Whether you’re running an online store, offering consulting services, or building something entirely new, they all h...

Daily Bulletin - avatar Daily Bulletin

“SMBs Are Building the Future While Australia Sleeps” — Marc Degli on AI, Innovation, and What Needs to Change

Australia’s startup scene has been called “emerging” for a decade — but for many founders, it still feels stalled. Government funding is mired in bureaucracy. Investors hedge their bets on “safe” deal...

Daily Bulletin - avatar Daily Bulletin

Hydrogen Pipe Infrastructure: A Guide to Future Networks

As Australia moves towards a cleaner energy future, hydrogen is emerging as a key player. But how do we get this promising energy source from production facilities to where it's needed? The answer l...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals